[In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma].
Polyethylene glycol (PEG-8000) -modified recombinant human interleukin-2 (PEG-rIL-2) is a cytokine with prolonged circulatory half-life. In this paper, the antitumor effects of PEG-rIL-2 against mouse uterine cervical carcinoma (U14) transplanted intraperitoneally or subcutaneously is reported. PEG-rIL-2 at different doses was administered intratumorally. The results showed that PEG-rIL-2 (4,500 IU, i.p., QD x 5) prolonged survival time of mice bearing ascites tumor as compared to rIL-2 (P < 0.01), but PEG-rIL-2 at lower doses was without therapeutic effect. In addition, compared to rIL-2, PEG-rIL-2 at different doses (1,500-13,500 IU, QD x 5) caused significant dose-dependent growth inhibition of solid tumor (P < 0.01) when the treatment started on lay 4 after subcutaneous inoculation of tumor.
Wang
L
L
Department of Internal Medicine, Rui Jin Hospital, Shanghai Second Medical University.
Wu
Y
Y
Zhang
Y
Y
D000818:Animals; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*
D007376:Interleukin-2; D011994:Recombinant Proteins; C067245:interleukin-2, polyethylene glycol-modified; D011092:Polyethylene Glycols